  The resistance to current antimicrobial agents , including fluoroquinolones<disease> , has continued to grow among various pathogens indicating a need for new antimicrobials to combat multi-drug resistant ( MDR) organisms. In June 2017 , delafloxacin received approval by the US Food and Drug Administration for the treatment of acute bacterial skin and skin-structure infections ( ABSSSIs) in adults caused by designated susceptible bacteria. Areas covered: This review describes the pharmacology , pharmacodynamics , pharmacokinetics , product information , efficacy , and safety of delafloxacin. Expert commentary: Delafloxacin is a novel oral and intravenous fluoroquinolone with activity against methicillin-resistant Staphylococcus<pathogen> aureus<pathogen> ( MRSA) and Pseudomonas<pathogen> aeruginosa<pathogen> , offering a new option for the treatment of ABSSSI and potentially for complicated urinary<disease> tract<disease> infections<disease> and severe community-acquired bacterial